Tetraphase Pharmaceuticals to Present at the Annual UBS Global Healthcare Conference

Tetraphase Pharmaceuticals to Present at the Annual UBS Global Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that Tetraphase Senior Vice President & Chief Financial Officer David Lubner will present at the annual UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 AM a.m. Eastern Time. The conference will take place at The Sheraton Hotel in New York City.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase’s lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.